Executive control in schizophrenia: a preliminary study on the moderating role of COMT Val158Met for comorbid alcohol and substance use disorders

References

• Alvarez JA, Emory E. Executive function and the frontal lobes: A meta-analytic review. Neuropsychol Rev 2006;16:17–42.
   PubMed Web of Science ®Google Scholar
• Baddeley A, Della Sala S. Working memory and executive control. Philos Trans R Soc Lond B Biol Sci 1996;351:1397–403.
   PubMed Web of Science ®Google Scholar
• Royall DR, Lauterbach EC, Cummings JL, Reeve A, Rummans TA, Kaufer DI, et al. Executive control function: A review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci 2002;14:377–405.
   PubMed Web of Science ®Google Scholar
• Delawalla Z, Barch DM, Fisher Eastep JL, Thomason ES, Hanewinkel MJ, Thompson PA, et al. Factors mediating cognitive deficits and psychopathology among siblings of individuals with schizophrenia. Schizophr Bull 2006;32:525–37.
   PubMed Web of Science ®Google Scholar
• Kerns JG, Berenbaum H. Cognitive impairments associated with formal thought disorder in people with schizophrenia. J Abnorm Psychol 2002;111:211–24.
   PubMed Web of Science ®Google Scholar
• Braw Y, Benozio A, Levkovitz Y. Executive functioning during full and partial remission (positive and negative symptomatic remission) of schizophrenia. Schizophr Res 2012;142:122–8.
   PubMed Web of Science ®Google Scholar
• Carrà G, Johnson S, Bebbington P, Angermeyer MC, Heider D, Brugha T, et al. The lifetime and past-year prevalence of dual diagnosis in people with schizophrenia across Europe: Findings from the European Schizophrenia Cohort (EuroSC). Eur Arch Psychiatry Clin Neurosci 2012;262:607–16.
   PubMed Web of Science ®Google Scholar
• Scheurich A. Neuropsychological functioning and alcohol dependence. Curr Opin Psychiatry 2005;18:319–23.
   PubMed Web of Science ®Google Scholar
• Tosato S, Ira E, Russo M, Iyegbe C, Lasalvia A, Di Forti M, et al. Association between the COMT gene and neurological abnormalities and poorer executive function in psychosis. Psychiatry Res 2015;230:742–3.
   PubMed Web of Science ®Google Scholar
• Bowie CR, Serper MR, Riggio S, Harvey PD. Neurocognition, symptomatology, and functional skills in older alcohol-abusing schizophrenia patients. Schizophr Bull 2005;31:175–82.
   PubMed Web of Science ®Google Scholar
• Serper MR, Bergman A, Copersino ML, Chou JC, Richarme D, Cancro R. Learning and memory impairment in cocaine-dependent and comorbid schizophrenic patients. Psychiatry Res 2000a;93:21–32.
   PubMed Web of Science ®Google Scholar
• Serper MR, Copersino ML, Richarme D, Vadhan N, Cancro R. Neurocognitive functioning in recently abstinent, cocaine-abusing schizophrenic patients. J Subst Abuse 2000b;11:205–13.
   PubMedGoogle Scholar
• Potvin S, Stavro K, Pelletier J. Paradoxical cognitive capacities in dual diagnosis schizophrenia: The quest for explanatory factors. J Dual Diagn 2012;8:35–47.
   Web of Science ®Google Scholar
• Joyal CC, Hallé P, Lapierre D, Hodgins S. Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia. Schizophr Res 2003;63:297–9.
   PubMed Web of Science ®Google Scholar
• McCleery A, Addington J, Addington D. Substance misuse and cognitive functioning in early psychosis: A 2 year follow-up. Schizophr Res 2006;88:187–91.
   PubMed Web of Science ®Google Scholar
• Potvin S, Briand C, Prouteau A, Bouchard RH, Lipp O, Lalonde P, et al. CANTAB explicit memory is less impaired in addicted schizophrenia patients. Brain Cogn 2005;59:38–42.
   PubMed Web of Science ®Google Scholar
• Potvin S, Joyal CC, Pelletier J, Stip E. Contradictory cognitive capacities among substance-abusing patients with schizophrenia: A meta-analysis. Schizophr Res 2008;100:242–51.
   PubMed Web of Science ®Google Scholar
• Yücel M, Bora E, Lubman DI, Solowij N, Brewer WJ, Cotton SM, et al. The impact of cannabis use on cognitive functioning in patients with schizophrenia: A meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull 2012;38:316–30.
   PubMed Web of Science ®Google Scholar
• Duva SM, Silverstein SM, Spiga R. Impulsivity and risk-taking in co-occurring psychotic disorders and substance abuse. Psychiatry Res 2011;186:351–5.
   PubMed Web of Science ®Google Scholar
• Meyer-Lindenberg A, Nichols T, Callicott JH, Ding J, Kolachana B, Buckholtz J, et al. Impact of complex genetic variation in COMT on human brain function. Mol Psychiatry 2006;11:867–77.
   PubMed Web of Science ®Google Scholar
• Eisenberg DP, Berman KF. Executive function, neural circuitry, and genetic mechanisms in schizophrenia. Neuropsychopharmacology 2010;35:258–77.
   PubMed Web of Science ®Google Scholar
• Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996;6:243–50.
   PubMedGoogle Scholar
• Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): Effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004;75:807–21.
   PubMed Web of Science ®Google Scholar
• Papaleo F, Burdick MC, Callicott JH, Weinberger DR. Epistatic interaction between COMT and DTNBP1 modulates prefrontal function in mice and in humans. Mol Psychiatry 2014;19:311–6.
   PubMed Web of Science ®Google Scholar
• Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: Longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005;57:1117–27.
   PubMed Web of Science ®Google Scholar
• Zammit S, Owen MJ, Evans J, Heron J, Lewis G. Cannabis, COMT and psychotic experiences. Br J Psychiatry 2011;199:380–5.
   PubMed Web of Science ®Google Scholar
• Henquet C, Rosa A, Krabbendam L, Papiol S, Fananás L, Drukker M, et al. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 2006;31:2748–57.
   PubMed Web of Science ®Google Scholar
• Szöke A, Schürhoff F, Méary A, Mathieu F, Chevalier F, Trandafir A, et al. Lack of influence of COMT and NET genes variants on executive functions in schizophrenic and bipolar patients, their first-degree relatives and controls. Am J Med Genet B Neuropsychiatr Genet 2006;141B:504–12.
   PubMed Web of Science ®Google Scholar
• Tunbridge EM, Dunn G, Murray RM, Evans N, Lister R, Stumpenhorst K, et al. Genetic moderation of the effects of cannabis: Catechol-O-methyltransferase (COMT) affects the impact of Δ9-tetrahydrocannabinol (THC) on working memory performance but not on the occurrence of psychotic experiences. J Psychopharmacol (Oxford) 2015;29:1146–51.
   PubMed Web of Science ®Google Scholar
• Verdejo-García A, Fagundo AB, Cuenca A, Rodriguez J, Cuyás E, Langohr K, et al. COMT val158met and 5-HTTLPR genetic polymorphisms moderate executive control in cannabis users. Neuropsychopharmacology 2013;38:1598–606.
   PubMed Web of Science ®Google Scholar
• Barch DM, Braver TS, Carter CS, Poldrack RA, Robbins TW. CNTRICS final task selection: Executive control. Schizophr Bull 2009;35:115–35.
   PubMed Web of Science ®Google Scholar
• Drake RE, Mueser KT, McHugo GJ, Clinician rating scales: Alcohol Use Scale (AUS), Drug Use Scale (DUS) and Substance Abuse Treatment Scale (SATS). In: Sederer L and Dickey B, editors. Outcomes assessment in clinical practice. Baltimore: Williams and Wilkins; p. 113–116, 1996.
   Google Scholar
• Roberts AC, Robbins TW, Everitt BJ. The effects of intradimensional and extradimensional shifts on visual discrimination learning in humans and non-human primates. Q J Exp Psychol B 1998;40:321–41.
   Google Scholar
• Barnett JH, Robbins TW, Leeson VC, Sahakian BJ, Joyce EM, Blackwell AD. Assessing cognitive function in clinical trials of schizophrenia. Neurosci Biobehav Rev 2010;34:1161–77.
   PubMed Web of Science ®Google Scholar
• Owen AM, Downes JJ, Sahakian BJ, Polkey CE, Robbins TW. Planning and spatial working memory following frontal lobe lesions in man. Neuropsychologia 1990;28:1021–34.
   PubMed Web of Science ®Google Scholar
• Computerized Cambridge Cognition. Computerized cognitive assessments: Powered by Cantab, 2013. [cited 2016 Apr 9] Available from: www.cambridgecognition.com
   Google Scholar
• Spitzer RL, Williams JB, Gibbon M, First MB. The structured clinical interview for DSM-III-R (SCID). I: History, rationale, and description. Arch Gen Psychiatry 1992;49:624–9.
   PubMed Web of Science ®Google Scholar
• Kay S, Opler LA, Fiszbein A. The structured clinical interview for the positive and negative syndromes of schizophrenia. New York, NY: Multi-Health Systems; 1992.
   Google Scholar
• Wechsler D. Manual for the Wechsler adult intelligence scale-revised. New York, NY: Psychological Corporation; 1981.
   Google Scholar
• Carrà G, Johnson S, Crocamo C, Angermeyer MC, Brugha T, Azorin JM, et al. Psychosocial functioning, quality of life and clinical correlates of comorbid alcohol and drug dependence syndromes in people with schizophrenia across Europe. Psychiatry Res 2016;239:301–7.
   PubMed Web of Science ®Google Scholar
• Costas J, Sanjuán J, Ramos-Ríos R, Paz E, Agra S, Ivorra JL, et al. Heterozygosity at catechol-O-methyltransferase Val158Met and schizophrenia: New data and meta-analysis. J Psychiatr Res 2011;45:7–14.
   PubMed Web of Science ®Google Scholar
• Schreiner AM, Dunn ME. Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: A meta-analysis. Exp Clin Psychopharmacol 2012;20:420–9.
   PubMed Web of Science ®Google Scholar
• Bilder RM, Volavka J, Czobor P, Malhotra AK, Kennedy JL, Ni X, et al. Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol Psychiatry 2002;52:701–7.
   PubMed Web of Science ®Google Scholar
• Galderisi S, Maj M, Kirkpatrick B, Piccardi P, Mucci A, Invernizzi G, et al. Catechol-O-methyltransferase Val158Met polymorphism in schizophrenia: Associations with cognitive and motor impairment. Neuropsychobiology 2005;52:83–9.
   PubMed Web of Science ®Google Scholar
• Joober R, Gauthier J, Lal S, Bloom D, Lalonde P, Rouleau G, et al. Catechol-O-methyltransferase Val-108/158-Met gene variants associated with performance on the Wisconsin Card Sorting Test. Arch Gen Psychiatry 2002;59:662–3.
   PubMed Web of Science ®Google Scholar
• Rosa A, Peralta V, Cuesta MJ, Zarzuela A, Serrano F, Martínez-Larrea A, et al. New evidence of association between COMT gene and prefrontal neurocognitive function in healthy individuals from sibling pairs discordant for psychosis. Am J Psychiatry 2004;161:1110–2.
   PubMed Web of Science ®Google Scholar
• Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF, et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA 2003;100:6186–91.
   PubMed Web of Science ®Google Scholar
• Bilder RM, Volavka J, Lachman HM, Grace AA. The catechol-O-methyltransferase polymorphism: Relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 2004;29:1943–61.
   PubMed Web of Science ®Google Scholar
• Carrà G, Johnson S. Variations in rates of comorbid substance use in psychosis between mental health settings and geographical areas in the UK. A systematic review. Soc Psychiatry Psychiatr Epidemiol 2009;44:429–47.
   PubMed Web of Science ®Google Scholar
• Bartoli F, Lax A, Crocamo C, Clerici M, Carrà G. Plasma adiponectin levels in schizophrenia and role of second-generation antipsychotics: A meta-analysis. Psychoneuroendocrinology 2015;56:179–89.
   PubMed Web of Science ®Google Scholar
• Carrà G, Scioli R, Monti MC, Marinoni A. Severity profiles of substance-abusing patients in Italian community addiction facilities: Influence of psychiatric concurrent disorders. Eur Addict Res 2006;12:96–101.
   PubMed Web of Science ®Google Scholar
• Saperstein AM, Kurtz MM. Current trends in the empirical study of cognitive remediation for schizophrenia. Can J Psychiatry 2013;58:311–8.
   PubMed Web of Science ®Google Scholar
• Baandrup L, Østrup Rasmussen J, Klokker L, Austin S, Bjørnshave T, Fuglsang Bliksted V, et al. Treatment of adult patients with schizophrenia and complex mental health needs: A national clinical guideline. Nord J Psychiatry 2016;70:231–40.
   PubMed Web of Science ®Google Scholar
• Luoto KE, Koivukangas A, Lassila A, Kampman O. Outcome of patients with dual diagnosis in secondary psychiatric care. Nord J Psychiatry 2016;70:470–6.
   PubMed Web of Science ®Google Scholar
• Carrà G, Cazzullo CL, Clerici M. The association between expressed emotion, illness severity and subjective burden of care in relatives of patients with schizophrenia. Findings from an Italian population. BMC Psychiatry 2012;12:140. doi:10.1186/1471-244X-12-140.
   PubMed Web of Science ®Google Scholar